Pierre Sesques

2.8k total citations
27 papers, 359 citations indexed

About

Pierre Sesques is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Pierre Sesques has authored 27 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Pathology and Forensic Medicine and 6 papers in Genetics. Recurrent topics in Pierre Sesques's work include CAR-T cell therapy research (16 papers), Lymphoma Diagnosis and Treatment (11 papers) and Virus-based gene therapy research (6 papers). Pierre Sesques is often cited by papers focused on CAR-T cell therapy research (16 papers), Lymphoma Diagnosis and Treatment (11 papers) and Virus-based gene therapy research (6 papers). Pierre Sesques collaborates with scholars based in France, United States and Germany. Pierre Sesques's co-authors include Nathalie A. Johnson, Emmanuel Bachy, Kai Rejeski, Frederick L. Locke, Alexandra Traverse‐Glehen, Gilles Salles, Michael D. Jain, Yucai Wang, Yi Lin and Marion Subklewe and has published in prestigious journals such as Blood, PLoS ONE and Frontiers in Microbiology.

In The Last Decade

Pierre Sesques

25 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre Sesques France 10 259 154 60 57 55 27 359
Juying Wei China 12 212 0.8× 75 0.5× 105 1.8× 39 0.7× 81 1.5× 44 380
Victor A. Chow United States 8 214 0.8× 77 0.5× 80 1.3× 32 0.6× 50 0.9× 29 359
Maria A. V. Marzolini United Kingdom 9 229 0.9× 84 0.5× 68 1.1× 16 0.3× 59 1.1× 21 310
LaQuisa Hill United States 11 265 1.0× 66 0.4× 72 1.2× 31 0.5× 132 2.4× 26 368
Xiaolu Long China 9 133 0.5× 41 0.3× 75 1.3× 19 0.3× 34 0.6× 22 233
Viktoria Blumenberg Germany 10 304 1.2× 46 0.3× 61 1.0× 13 0.2× 51 0.9× 32 361
Hema Dave United States 9 150 0.6× 28 0.2× 72 1.2× 21 0.4× 56 1.0× 27 241
Chunrong Tong China 11 337 1.3× 29 0.2× 108 1.8× 37 0.6× 113 2.1× 50 450
Yasmin Hazrat United States 3 376 1.5× 186 1.2× 39 0.7× 32 0.6× 331 6.0× 6 553
Eduardo Marinho France 10 235 0.9× 130 0.8× 26 0.4× 24 0.4× 149 2.7× 17 538

Countries citing papers authored by Pierre Sesques

Since Specialization
Citations

This map shows the geographic impact of Pierre Sesques's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Sesques with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Sesques more than expected).

Fields of papers citing papers by Pierre Sesques

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Sesques. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Sesques. The network helps show where Pierre Sesques may publish in the future.

Co-authorship network of co-authors of Pierre Sesques

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Sesques. A scholar is included among the top collaborators of Pierre Sesques based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Sesques. Pierre Sesques is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blasi, Roberta Di, Louise Roulin, Véronique Meignin, et al.. (2025). TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas. Blood Advances. 9(18). 4693–4704.
2.
3.
4.
Ranchon, Florence, Étienne Chatelut, Juliette Lambert, et al.. (2023). Anticorps monoclonaux conjugués et bispécifiques en cancérologie – compte rendu de la Journée de Saint Louis 2022. Bulletin du Cancer. 110(12). 1343–1351. 4 indexed citations
5.
Rejeski, Kai, Doris K. Hansen, Radhika Bansal, et al.. (2023). The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. Journal of Hematology & Oncology. 16(1). 88–88. 48 indexed citations
6.
Tabaa, Yassine Al, Clément Bailly, Anne‐Ségolène Cottereau, et al.. (2023). Low Tmtv Influences Response and Outcomes in R/R DLBCL 3L+ Patients Treated with CAR-T Cells : First Results of FDG-PET/CT Analysis in the French Descar-T Registry. Blood. 142(Supplement 1). 3019–3019. 1 indexed citations
7.
Combes, Jean‐Damien, et al.. (2022). Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. EClinicalMedicine. 54. 101674–101674. 26 indexed citations
8.
Luque-Paz, David, Pierre Sesques, Florent Wallet, Emmanuel Bachy, & Florence Ader. (2022). B-cell malignancies and COVID-19: a narrative review. Clinical Microbiology and Infection. 29(3). 332–337. 6 indexed citations
9.
Rejeski, Kai, Andreas Burchert, Gloria Iacoboni, et al.. (2022). Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Advances. 6(16). 4719–4725. 36 indexed citations
10.
Cordeil, Stéphanie, Estelle Bourbon, Emmanuelle Ferrant, et al.. (2022). Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas. Leukemia & lymphoma. 64(3). 707–711. 9 indexed citations
11.
Luque-Paz, David, Pierre Sesques, Florent Wallet, Emmanuel Bachy, & Florence Ader. (2022). The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose. Expert Review of Anti-infective Therapy. 20(9). 1155–1162. 2 indexed citations
12.
Wallet, Florent, Pierre Sesques, Perrine Devic, et al.. (2021). CAR-T cell: Toxicities issues: Mechanisms and clinical management. Bulletin du Cancer. 108(10). S117–S127. 10 indexed citations
13.
14.
Trécourt, Alexis, Claire Mauduit, Vanessa Szablewski, et al.. (2021). Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas. The American Journal of Surgical Pathology. 46(1). 58–70. 14 indexed citations
15.
Sesques, Pierre, Jessie Bourcier, Camille Golfier, et al.. (2020). Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematological Oncology. 38(2). 137–145. 4 indexed citations
16.
Ranchon, Florence, Laure Huot, Isabelle Carpentier, et al.. (2020). Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects. PLoS ONE. 15(12). e0243309–e0243309. 4 indexed citations
17.
Bal, Antonin, Guy Oriol, Laurence Josset, et al.. (2019). Metagenomic Investigation of Torque Teno Mini Virus-SH in Hematological Patients. Frontiers in Microbiology. 10. 4 indexed citations
18.
Belin, Cathérine, C Simard, Xavier Ayrignac, et al.. (2019). JS1.4 Neurological follow-up of neurotoxicity after CAR T cell therapy in lymphoma patients: A French neurological multi-center survey. Neuro-Oncology. 21(Supplement_3). iii5–iii5. 2 indexed citations
19.
Thiéblemont, Catherine, Steven Le Gouill, Roberta Di Blasi, et al.. (2019). S1600 REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM. HemaSphere. 3(S1). 736–737. 2 indexed citations
20.
Bal, Antonin, Clémentine Sarkozy, Laurence Josset, et al.. (2018). Metagenomic Next-Generation Sequencing Reveals Individual Composition and Dynamics of Anelloviruses during Autologous Stem Cell Transplant Recipient Management. Viruses. 10(11). 633–633. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juying Wei Breakdown of academic impact, for papers by Victor A. Chow Breakdown of academic impact, for papers by Maria A. V. Marzolini Breakdown of academic impact, for papers by LaQuisa Hill Breakdown of academic impact, for papers by Xiaolu Long Breakdown of academic impact, for papers by Viktoria Blumenberg Breakdown of academic impact, for papers by Hema Dave Breakdown of academic impact, for papers by Chunrong Tong Breakdown of academic impact, for papers by Yasmin Hazrat Breakdown of academic impact, for papers by Eduardo Marinho
Rankless by CCL
2026